DSGN
Design Therapeutics, Inc. NASDAQ Listed Mar 29, 2021$14.10
Pre-mkt
$14.30
+0.56%
Mkt Cap $880.6M
52w Low $3.10
77.7% of range
52w High $17.25
50d MA $11.64
200d MA $8.53
P/E (TTM)
-10.9x
EV/EBITDA
-6.6x
P/B
3.6x
Debt/Equity
0.0x
ROE
-32.8%
P/FCF
-9.9x
RSI (14)
—
ATR (14)
—
Beta
1.58
50d MA
$11.64
200d MA
$8.53
Avg Volume
318.5K
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
CIK (SEC)
Phone
858 293 4900
6005 Hidden Valley Road · Carlsbad, CA 92011 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | AMC | -0.36 | -0.29 | +19.4% | 12.81 | +1.5% | +23.3% | -13.9% | -2.2% | -1.0% | +1.8% | — |
| Mar 9, 2026 | AMC | -0.38 | -0.27 | +28.9% | 10.37 | +1.6% | -3.7% | +0.2% | +0.1% | +1.0% | +8.6% | — |
| Nov 5, 2025 | AMC | -0.34 | -0.30 | +11.8% | 6.55 | -1.7% | +4.9% | +10.0% | -1.7% | +4.4% | -1.9% | — |
| Aug 7, 2025 | AMC | -0.32 | -0.34 | -6.2% | 3.97 | +4.3% | +7.8% | +12.6% | +3.3% | +8.8% | -4.8% | — |
| May 7, 2025 | AMC | -0.28 | -0.31 | -10.7% | 3.33 | -0.9% | +5.7% | -0.6% | +3.4% | -1.4% | -9.8% | — |
| Mar 10, 2025 | AMC | -0.28 | -0.24 | +14.3% | 4.87 | +0.0% | +9.4% | -6.9% | -4.8% | -0.2% | +4.7% | — |
| Nov 7, 2024 | AMC | -0.26 | -0.23 | +11.5% | 5.79 | -0.3% | +0.7% | +13.4% | +4.5% | +8.5% | -19.7% | — |
| Aug 5, 2024 | AMC | -0.25 | -0.21 | +16.0% | 4.66 | +0.0% | -9.7% | -3.1% | -0.5% | +4.4% | +0.2% | — |
| May 8, 2024 | AMC | -0.28 | -0.20 | +28.6% | 4.69 | +3.2% | +1.7% | -4.2% | -0.4% | -1.3% | +0.4% | — |
| Mar 19, 2024 | AMC | -0.32 | -0.21 | +34.4% | 2.59 | +12.4% | +12.0% | +12.4% | +16.6% | -1.6% | -4.5% | — |
| Nov 13, 2023 | AMC | -0.42 | -0.28 | +33.3% | 2.05 | +6.8% | +11.7% | +1.3% | -5.2% | +0.9% | +0.5% | — |
| Aug 14, 2023 | AMC | -0.41 | -0.36 | +12.2% | 7.33 | -61.4% | -70.4% | -1.8% | -0.5% | -1.4% | -1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10 | RBC Capital | Maintains | Outperform → Outperform | — | $10.37 | $10.54 | +1.6% | -3.7% | +0.2% | +0.1% | +1.0% | +8.6% |
| Dec 3 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $8.94 | $9.55 | +6.8% | +9.3% | +0.5% | -0.5% | +0.9% | -6.0% |
| Nov 20 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $7.34 | $8.09 | +10.2% | +7.2% | +6.1% | +3.5% | +8.9% | -0.4% |
| Nov 6 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $6.55 | $6.44 | -1.7% | +4.9% | +10.0% | -1.7% | +4.4% | -1.9% |
| Aug 6 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $4.66 | $4.66 | +0.0% | -9.7% | -3.1% | -0.5% | +4.4% | +0.2% |
| May 7 | Piper Sandler | Upgrade | Neutral → Overweight | — | $3.65 | $3.88 | +6.3% | +28.5% | +0.0% | +1.7% | -4.2% | -0.4% |
| Mar 20 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $2.59 | $2.91 | +12.4% | +12.0% | +12.4% | +16.6% | -1.6% | -4.5% |
| Mar 20 | Wedbush | Maintains | Neutral → Neutral | — | $2.59 | $2.91 | +12.4% | +12.0% | +12.4% | +16.6% | -1.6% | -4.5% |
| Nov 14 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $2.05 | $2.19 | +6.8% | +11.7% | +1.3% | -5.2% | +0.9% | +0.5% |
| Aug 15 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $7.33 | $2.83 | -61.4% | -70.4% | -1.8% | -0.5% | -1.4% | -1.9% |
| Aug 15 | Wedbush | Downgrade | Outperform → Neutral | — | $7.33 | $2.83 | -61.4% | -70.4% | -1.8% | -0.5% | -1.4% | -1.9% |
| Aug 15 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $7.33 | $2.83 | -61.4% | -70.4% | -1.8% | -0.5% | -1.4% | -1.9% |
| May 10 | RBC Capital | Maintains | Outperform → Outperform | — | $7.55 | $7.67 | +1.6% | -11.7% | -4.5% | +4.2% | +2.6% | -7.8% |
| May 10 | Wedbush | Maintains | Outperform → Outperform | — | $7.55 | $7.67 | +1.6% | -11.7% | -4.5% | +4.2% | +2.6% | -7.8% |
| May 4 | Goldman Sachs | Upgrade | Sell → Neutral | — | $7.19 | $7.37 | +2.5% | +5.4% | +0.0% | +0.3% | -0.7% | -11.7% |
| Mar 15 | RBC Capital | Maintains | Outperform → Outperform | — | $7.07 | $7.23 | +2.3% | -0.8% | +0.3% | -7.8% | +0.6% | -4.4% |
| Dec 9 | SVB Leerink | Maintains | Outperform → Outperform | — | $8.46 | $8.68 | +2.6% | -7.1% | +10.1% | +4.4% | -1.7% | -8.7% |
| Dec 8 | RBC Capital | Maintains | Outperform → Outperform | — | $12.69 | $8.30 | -34.6% | -33.3% | -7.1% | +10.1% | +4.4% | -1.7% |
| Aug 9 | Wedbush | Maintains | Outperform → Outperform | — | $21.42 | $24.85 | +16.0% | +2.7% | +6.0% | -1.2% | +8.1% | +2.7% |
| Jun 10 | Wedbush | Maintains | Outperform → Outperform | — | $14.03 | $14.24 | +1.5% | -4.8% | -2.5% | +3.3% | +1.9% | -3.4% |
| May 24 | Goldman Sachs | Maintains | Sell → Sell | — | $12.99 | $12.60 | -3.0% | -8.2% | -1.0% | +1.3% | +8.3% | -3.6% |
| May 10 | SVB Leerink | Maintains | Outperform → Outperform | — | $11.07 | $11.27 | +1.8% | -0.4% | -10.2% | +7.9% | +2.2% | +9.0% |
| May 2 | RBC Capital | Maintains | Outperform → Outperform | — | $11.94 | $12.47 | +4.4% | +4.2% | -0.8% | +1.5% | -3.2% | -7.6% |
| Jan 19 | Goldman Sachs | Maintains | Sell → Sell | — | $14.85 | $14.32 | -3.6% | -5.9% | -11.2% | -10.0% | +5.3% | -4.3% |
| Apr 20 | SVB Leerink | Maintains | Outperform → Outperform | — | $23.00 | $22.17 | -3.6% | -7.2% | -8.4% | -2.7% | +1.3% | +5.8% |
| Apr 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $23.00 | $22.17 | -3.6% | -7.2% | -8.4% | -2.7% | +1.3% | +5.8% |
| Apr 20 | Goldman Sachs | Maintains | Neutral → Neutral | — | $23.00 | $22.17 | -3.6% | -7.2% | -8.4% | -2.7% | +1.3% | +5.8% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
DSGN's appointment of Pratik Shah, Ph.D. as an executive signals potential strategic shifts in leadership that could affect operational direction and investor confidence, warranting close monitoring of upcoming guidance and strategic announcements.
Apr 1
8-K
Design Therapeutics, Inc. -- 8-K Filing
Design Therapeutics (DSGN) reported $219.8 million in cash supporting three ongoing clinical trials, with DT-818 dosing expected in early 2026, providing runway for near-term pipeline advancement.
Mar 9
Data updated apr 25, 2026 5:50am
· Source: massive.com